We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for atezolizumab (Roche Products Pty Limited)
Active ingredients
atezolizumab
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
atezolizumab in combinatinon with bevacizumab, is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Therapeutic area
Oncology